Industries > Pharma > Artemisinin Combination Therapy Market Forecast 2020-2030
Artemisinin Combination Therapy Market Forecast 2020-2030
Artemisinin Combination Therapy Market Forecast 2020-2030: Forecasts and Analysis by Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), by Route of Administration (Oral, Intravenous, Intramuscular), by Distribution Channel (Hospital Pharmacies, Retail Stores, Drug Stores) and Geography with Profiles of Leading Companies
According to the report published by Visiongain, the Artemisinin Combination Therapy market is projected at USD 532.8 million in 2020. During the forecast period 2020-2030, expansion is expected at a CAGR of 8.5 percent fold. There has been a tremendous increase in supply for combination therapy with artemisinin (ACT) in recent years regarding its World Health Organization acceptance as first-line malaria treatment.
For malaria combat attempts, the availability and use of efficient malaria therapy is crucial. Since 2001, the World Health Organization has suggested the use of combination therapy based on Artemisinin (ACT) to treat uncomplicated P. falciparum tuberculosis, one of the most prevalent and hazardous types of malaria. Unfortunately, monotherapies or guaranteed non-quality ACTs are faster and wider than quality-assured ACTs, especially in the private sector. Not only does the use of substandard medicines fail to cure the disease, it also has the ability to boost artemisinin opposition to creation and propagation.
The risk of malaria in endemic nations has declined dramatically in recent years. The scale-up of efficient instruments for diagnosing and treating malaria has performed a major part in this success in public health, and the ongoing accessibility of established products for malaria situation leadership is crucial to sustain and expand the profits. However, malaria treatment and diagnostic economies are facing a amount of difficult business dynamics that have produced incompatible availability of products in the previous, volatile demand, important cost fluctuations, and suboptimal resource allocation. Given the magnitude of the malaria scenario leadership commodities market and its significance for public health, discovering methods to guarantee higher flexibility in this industry is critical to a wide range of stakeholders including policymakers, industry members and, most notably, people with malaria.
For the treatment of P. falciparum malaria, combined therapy based on artemisinin (ACT) is currently suggested. A drug from a different class is coupled with fast working artemisinin-based compounds. Companion medicines include lumefantrine, mefloquine, amodiaquine, sulfadoxine / pyrimethamine, chlorproguanil / dapsone and piperaquine. A drug from a different class is coupled with fast working artemisinin-based compounds. Companion medicines include lumefantrine, mefloquine, amodiaquine, sulfadoxine / pyrimethamine, chlorproguanil / dapsone and piperaquine. Dihydroartemisininin, artesunate and artemether are derivatives of artemisinin. A co-formulated drug is one that combines in one tablet two distinct drugs; this is essential to guarantee that both drugs are used.
The advantages of ACTs are their elevated efficacy, rapid intervention and lower probability of creating opposition. To create the greatest use of them, especially since there is probable to be no option for several years, it is critical to tackle service, entry and price problems.
The challenges for medium products and raw materials also apply to the economies. Most of the worldwide supply of artemisinin, the main raw material in the manufacture of artemisinin-based combination therapies (ACTs) (the suggested therapy of uncomplicated malaria by the WHO) and injectable artesunate (the favored therapy of serious malaria by the WHO) comes from agricultural sources. This vegetable item needs from the original cultivation of the plant to the manufacturing and shipping of an ACT a 12 to 14-month period. The manufacturing of semi-synthetic artemisinin has a smaller lead time, but the present complete worldwide capability for semi-synthetic commodity synthesis is equal to only 25% of worldwide supply for artemisinin. Artemisinin price volatility has resulted to worries about feasible narrowing of ACT demand, leading in important danger to industry members and nurses whose life rely on prepared access to these drugs.
Demand was expected across three avenues of entry: the government industry, the official personal industry, and the official personal industry includes private drug shops, vendors and general retailers that sell medicines ACT procurement was also expected in three industry classifications: the public sector, the private sector subsidized competition and the personal industry non-subsidized (discount) competition. When evaluating these forecasts, several caveats are essential to bear in mind. The anti-malarial needs and request forecasts are focused on the extrapolation of historical household study information on the incidence of fever, malaria incidence, wanting therapy, screening, and antimalarial therapy gathered from kids under five years of era. In any of these developments, new and drastic changes would change the forecasts ACT and RDT procurement forecasts are largely dependent on current financing commitments and historical developments, as compared to modifications in disease burden or nurse behaviour; modifications in global donor donations or quarterly domestic financing allocations could alter general procurement projections. Other unforeseen occurrences–such as the use of ACTs for mass substance administration initiatives, the effect of mosquito virus deployment on ACT supply, and others–could also change the national and international perspective for these goods.
A fast increase in the reduction of bacterial exposure to ACTs in Southeast Asia or the transfer of sensitive bacteria outside the GMS area and to Africa could have important repercussions for both disease combat strategies and stock prices. Politicians would have several feasible reactions to consider in such circumstances. The most instant objective would be to guarantee that people with ACT-resistant infection can endure the infection using the available therapy instruments. This could imply revising treatment guidelines to advise shorter durations of therapy, adopting triple drug mixes rapidly shifting across a district or country in therapy regimenClearing an infection may decrease the moment it takes for an affected person to convey malaria to another person. Another strategy to transmission reduction, however, is to administer antimalarial drugs that prevent the parasite’s sexual stage (such as primaquine) along with periodic ACT
INNOVATION IN TOOLS
The ultimate significant challenge confronting future markets in the diagnosis and therapy of malaria commodities is the effect of new instruments and solutions to diagnosis, therapy and avoidance of malaria. Several significant technologies have been studied and integrated in mosquito prevention and elimination programs in latest years, including injectable and rectal artesunate formulations for the therapy of serious disease, fetal dispersible formulations of ACTs and increased use of SMC in areas where disease infection happens over a span of moment that is both linear and of restricted lengthFurthermore, the latest request for statutory authorization of tafenoquine provides hope in the therapy of Plasmodium vivax (P.vivax) diseases, offering a full batch administration (substituted a 14-day primaquine regimen) for radical cure for nurses without enzymatic deficiencies (Glucose-6-phosphate dehydrogenase (G6PD) defect) that would prevent them from getting this medicine. Each of these measures advantages a particular customer group or group form and together they have led to reducing the malaria strain.
Why you should buy Artemisinin Combination Therapy Market Forecast 2020-2030: Forecasts and Analysis by Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), By Route Of Administration (Oral, Intravenous, Intramuscular), By Distribution Channel (Hospital Pharmacies, Retail Stores, Drug Stores) and Geography, with Profiles of Leading Companies.
Visiongain’s comprehensive analysis contains highly quantitative content delivering solid conclusions benefiting your analysis and illustrates new opportunities and potential revenue streams helping you to remain competitive. This definitive report will benefit your decision making and help to direct your future business strategy.
We guarantee in this 171 page report you will receive the following key information
– View Artemisinin Combination Therapy market forecasts and analysis from 2020-2030 to keep you ahead of your competitors and ensure you exploit key business opportunities
– The report provides detailed sales projections of the market, the competitors, and the commercial drivers and restraints allowing you to more effectively compete in the market. In addition to market forecasts from 2020-2030, our new study shows current market data, original critical analysis, and revealing insight into commercial developments
– Artemisinin Combination Therapy revenue forecast
– Artemisinin Combination Therapy connections forecast
– Examine 122 tables, charts, and graphs.
– Let our analysts present you with a thorough assessment of the current and future Artemisinin Combination Therapy market prospects.
– This analysis will achieve quicker, easier understanding. Also you will gain from our analyst’s industry expertise allowing you to demonstrate your authority on the Artemisinin Combination Therapy sector
– Discover sales predictions for the key end use submarkets from 2020-2030
– What are the dynamics of the Artemisinin Combination Therapy industry? Which submarkets will generate the most revenue? Use our forecasts and expert insight to grow your business and give you more industry influence. Find where you can gain and how your organisation can succeed. Avoid falling behind. Stay informed about the potential for each of these Artemisinin Combination Therapy submarkets with individual forecasts and analysis from 2020-2030.
– Type submarket forecast 2020-2030
– Administration submarket forecast 2020-2030
– Distribution Channel submarket forecast 2020-2030
– Learn about the market prospects for the leading Artemisinin Combination Therapy market segments 2020-2030
– How will various value chain members perform over the forecast period? Discover where the highest revenue potential lies from 2020-2030, learning about how Artemisinin Combination Therapy revenue trickles down through the various market segments. These forecasts will also reveal the competitive landscape. You will see what is happening, explaining the challenges, trends, competitors, and market opportunities. Our report reveals forecasts for the 3 leading segmentations as follows.
– Type Revenue Forecast 2020-2030
– Dihydroartemisinin-piperaquine Market Forecast, 2020-2030
– Artesunate-chlorproguanil-dapsone Market Forecast, 2020-2030
– Artesunate-atovaquone-proguanil Market Forecast, 2020-2030
– Artesunate-mefloquine Market Forecast, 2020-2030
– Artemether-lumefantrine Market Forecast, 2020-2030
– Artesunate-pyronaridine Market Forecast, 2020-2030
– Artesunate-amodiaquine Market Forecast, 2020-2030
– Artesunate-sulfadoxine-pyrimethamine Market Forecast, 2020-2030
– Other Type Market Forecast, 2020-2030
– Administration Revenue Forecast 2020-2030
– Oral Market Forecast, 2020-2030
– Intravenous Market Forecast, 2020-2030
– Intramuscular Market Forecast, 2020-2030
– Other Administration Market Forecast, 2020-2030
– Distribution Channel Revenue Forecast 2020-2030
– Hospitals Pharmacies Market Forecast, 2020-2030
– Retail Stores Market Forecast, 2020-2030
– Drug Stores Market Forecast, 2020-2030
– Other Distribution Channel Market Forecast, 2020-2030
– Understand the prospects for the 4 regional and the leading 12 national Artemisinin Combination Therapy markets – where will the highest revenues and opportunities occur?
– Learn about the market potential for Artemisinin Combination Therapy companies in the developed and developing countries, from 2019 onwards. You will see where and how opportunities exist with revealing individual market forecasts and analysis from 2020-2030 for 12 leading national markets by revenue, as well as segmented regional forecasts
– North America Artemisinin Combination Therapy revenue forecast 2020-2030
– US Artemisinin Combination Therapy revenue forecast 2020-2030
– Canada Artemisinin Combination Therapy revenue forecast 2020-2030
– Mexico Artemisinin Combination Therapy revenue forecast 2020-2030
– North America Artemisinin Combination Therapy by Type revenue forecast 2020-2030
– North America Artemisinin Combination Therapy by Administration revenue forecast 2020-2030
– North America Artemisinin Combination Therapy by Distribution Channel revenue forecast 2020-2030
– Asia Pacific Artemisinin Combination Therapy revenue forecast 2020-2030
– China Artemisinin Combination Therapy revenue forecast 2020-2030
– Japan Artemisinin Combination Therapy revenue forecast 2020-2030
– India Artemisinin Combination Therapy revenue forecast 2020-2030
– Australia Artemisinin Combination Therapy revenue forecast 2020-2030
– Rest of Asia Pacific Artemisinin Combination Therapy revenue forecast 2020-2030
– Asia Pacific Artemisinin Combination Therapy by Type revenue forecast 2020-2030
– Asia Pacific Artemisinin Combination Therapy by Administration revenue forecast 2020-2030
– Asia Pacific Artemisinin Combination Therapy by Distribution Channel revenue forecast 2020-2030
– European Artemisinin Combination Therapy revenue forecast 2020-2030
– Germany Artemisinin Combination Therapy revenue forecast 2020-2030
– UK Artemisinin Combination Therapy revenue forecast 2020-2030
– France Artemisinin Combination Therapy revenue forecast 2020-2030
– Italy Artemisinin Combination Therapy revenue forecast 2020-2030
– Spain Artemisinin Combination Therapy revenue forecast 2020-2030
– Rest of Europe Artemisinin Combination Therapy revenue forecast 2020-2030
– European Artemisinin Combination Therapy by Type revenue forecast 2020-2030
– European Artemisinin Combination Therapy by Administration revenue forecast 2020-2030
– European Artemisinin Combination Therapy by Distribution Channel revenue forecast 2020-2030
– Rest of World Artemisinin Combination Therapy revenue forecast 2020-2030
– Rest of World Artemisinin Combination Therapy by Type revenue forecast 2020-2030
– Rest of World Artemisinin Combination Therapy by Administration revenue forecast 2020-2030
– Rest of World Artemisinin Combination Therapy by Distribution Channel revenue forecast 2020-2030
– Explore the factors affecting Artemisinin Combination Therapy product developers, and everyone within the value chain. Learn about the forces influencing market dynamics.
– Discover what the present and future outlook for business will be. Learn about the following business critical issues
– Research and development (R&D) strategy
– Technological issues and constraints.
– Competition from new product types
– Increasing specialisation by leading players
– Increasing industry consolidation.
– Advances in product quality
– Analysis of barriers to entry
– Identify who the leading companies are in the Artemisinin Combination Therapy industry
– Our report reveals the technologies and companies which hold the greatest potential. In particular, exploring and analyzing the activities of these companies: See where the expected gains will be. View visiongain’s assessment of the prospects for established competitors, rising companies, and new market entrants. Our work explains that potential, helping you stay ahead. Gain a thorough understanding of the competitive landscape with profiles of 10 leading Artemisinin Combination Therapy companies examining their positioning, capabilities, product portfolios, R&D activity, services, focus, strategies, M&A activity, and future outlook.
Leading Companies in the Global Artemisinin Combination Therapy Market
Guilin Pharmaceutical Co., Ltd
KPC Pharmaceuticals, Inc
Cipla Inc.
Shelys Africa Pharmaceuticals Ltd.
Ipca Laboratories Ltd.
Hovid-Integrated Global Pharmaceutical Partner
DENK PHARMA GmbH & Co.KG
Novartis AG
Mylan N.V
Calyx Chemicals & Pharmaceutical Ltd.
Discover Information found nowhere else in this independent assessment of the Artemisinin Combination Therapy market
The Artemisinin Combination Therapy Market Forecast 2020-2030: Forecasts and Analysis By Type, By Administration, By Distribution Channel and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Artemisinin Combination Therapy sector analysis. With the independent business intelligence found only in our work, you will discover where the prospects are for profit. In particular, our new research provides you with key strategic advantages: Our informed forecasts, independent and objective analysis, exclusive interviews and revealing company profiles will provide you with that necessary edge, allowing you to gain ground over your competitors.
With this report you are less likely to fall behind in knowledge or miss crucial business opportunities. You will save time and receive recognition for your market insight. See how you this report could benefit and enhance your research, analysis, company presentations and ultimately your individual business decisions and your company’s prospects.
What makes this report unique?
Visiongain’s research methodology involves an exclusive blend of primary and secondary sources providing informed analysis. This methodology allows insight into the key drivers and restraints behind market dynamics and competitive developments. The report therefore presents an ideal balance of qualitative analysis combined with extensive quantitative data including global, submarket and regional markets forecasts from 2020-2030
How the Artemisinin Combination Therapy Market Forecast 2020-2030: Forecasts and Analysis By Type, By Administration, By Distribution Channel and and Geography, with Profiles of Leading Companies report can benefit you
Visiongain’s report is for anyone requiring analysis of the Artemisinin Combination Therapy market. You will discover market forecasts, technological trends, predictions and expert opinion providing you with independent analysis derived from our extensive primary and secondary research. Only by purchasing this report will you receive this critical business intelligence revealing where revenue growth is likely and where the lucrative potential market prospects are. Don’t miss this key opportunity to gain a competitive advantage.
Avoid falling behind your competitors, overlooking critical business opportunities or losing industry influence. In our new report you will discover forecasts from 2020-2030 at the global, submarket, and national level. The report also assesses technologies, competitive forces and expected product pipeline developments. Read on to discover the prospects for the Artemisinin Combination Therapy sector and find out what its future market prospects are.
If you buy our report today your knowledge will stay one step ahead of your competitors. Discover how our report could benefit your research, analyses and strategic decisions, saving you time. To gain an understanding of how to tap into the potential of this market and stay one step ahead of the competition you must order now our report the Artemisinin Combination Therapy Market Forecast 2020-2030: Forecasts and Analysis By Type, By Administration, By Distribution Channel and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Artemisinin Combination Therapy sector analysis. Avoid missing out – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Download sample pages
Complete the form below to download your free sample pages for Artemisinin Combination Therapy Market Forecast 2020-2030Download sample pages
Complete the form below to download your free sample pages for Artemisinin Combination Therapy Market Forecast 2020-2030
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034
The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.
11 April 2024
